Viridian Therapeutics Announces Important Public Offering
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on creating innovative medicines for serious and rare conditions, has captured attention today by revealing the pricing details of an increased underwritten public offering. This offering includes shares of its common stock and shares of Series B non-voting convertible preferred stock.
Offering Details
The company intends to offer a total of 10,666,600 shares of common stock at a price of $18.75 each, alongside 20,000 Series B preferred shares priced at $1,250.06250 per share. These preferred shares can be converted into 1,333,400 shares of common stock. Interestingly, Viridian has also given underwriters a 30-day option to acquire an additional 1,800,000 shares at the public offering price, adjusted for any applicable discounts and commissions.
Expected Financial Outcome
The anticipated gross proceeds from this offering are expected to be around $225 million before subtracting any underwriting fees, commissions, and other estimated costs that Viridian may incur. The company is confident that this influx of funds will strategically enhance its clinical development initiatives and support ongoing operational needs.
Closing Timeline and Fund Utilization
The offering is expected to close around a date that’s contingent on customary conditions. Once finalized, the funds raised through this public offering will be directed towards accelerating research and development efforts, including current clinical projects and fulfilling working capital needs.
Collaborative Partnerships
Notable financial institutions such as Jefferies, Goldman Sachs & Co. LLC, Stifel, and RBC Capital Markets are serving as joint book-running managers for this public offering, with Wedbush PacGrow stepping in as a co-manager.
Viridian’s Clinical Development Journey
Viridian is leading the way in developing innovative treatments for thyroid eye disease (TED). The company is currently running a significant program for their product veligrotug, which includes two large global phase 3 trials known as THRIVE and THRIVE-2. These trials are aimed at determining the medication's effectiveness and safety for patients experiencing both active and chronic forms of TED.
New Therapy Opportunities
In addition, Viridian is advancing another promising candidate, VRDN-003, which is under evaluation as a potential top-tier subcutaneous treatment for TED. This development also includes two global phase 3 clinical trials, REVEAL-1 and REVEAL-2, concentrating on VRDN-003’s safety and efficacy for affected individuals.
New Therapeutics for Autoimmune Diseases
Alongside its work in TED, Viridian is investigating a new group of neonatal Fc receptor (FcRn) inhibitors, specifically VRDN-006 and VRDN-008. These investigational treatments show significant promise for use in various autoimmune diseases, further expanding Viridian’s influence in the biopharmaceutical sector.
About Viridian Therapeutics, Inc.
Viridian Therapeutics is dedicated to designing and developing potentially transformative medicines aimed at serious and rare diseases. By leveraging their expertise in antibody discovery and protein engineering, the company is positioning itself to advance several unique therapeutic candidates targeting well-known drug targets across multiple disease areas.
Frequently Asked Questions
What is the purpose of the public offering announced by Viridian?
The public offering is intended to generate funding that will support clinical development programs and help provide working capital for general corporate needs.
How much gross revenue is expected from the offering?
Viridian is anticipating gross proceeds of about $225 million from the offering, before accounting for underwriting fees and other expenses.
Which financial institutions are involved in this offering?
Financial institutions such as Jefferies, Goldman Sachs & Co. LLC, Stifel, and RBC Capital Markets are acting as joint book-running managers for the public offering.
What therapies is Viridian currently developing?
Viridian is focused on treatments for thyroid eye disease and is also exploring neonatal Fc receptor inhibitors for various autoimmune disorders.
Is there a closure date for the offering?
The offering is likely to close around mid-September, pending customary conditions.
